Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 2.08 is 21% below its 5-year average of 2.63, around the middle of its 5-year range (0.67–4.91).
As of the fiscal period ended Tuesday, June 30, 2026. 33.09% below its 12-month average of 3.11.
Reported quarterly current ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 2.08.
CURRENT RATIO
2.08
CURRENT RATIO AVG TTM
3.11
CURRENT RATIO AVG 3Y
2.49
CURRENT RATIO AVG 5Y
2.63
CURRENT RATIO AVG 10Y
2.95
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-33.09%
CURRENT VS 3Y AVG
-16.33%
CURRENT VS 5Y AVG
-20.90%
CURRENT VS 10Y AVG
-29.51%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.58
median of 778 covered companies
CURRENT VS SECTOR MEDIAN
-41.86%
vs the sector median at left
Market Cap
$4.10M
Current Ratio
0.87
TTM Avg
1.88
3Y Avg
4.97
5Y Avg
8.67
Market Cap
$4.40M
Current Ratio
40.30
TTM Avg
26.48
3Y Avg
43.98
5Y Avg
50.08
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aptevo Therapeutics Inc. (APVO) | $4.00M | 2.08 | 3.11 | 2.49 | 2.63 |
| Ernexa Therapeutics Inc. (ERNA)vs › | $4.04M | 2.01 | 0.91 | 1.26 | 1.78 |
| Processa Pharmaceuticals, Inc. (PCSA)vs › | $4.10M | 0.87 | 1.88 | 4.97 | 8.67 |
| GRI Bio, Inc. (GRI)vs › | $4.15M | 10.30 | 3.34 | 1.98 | 1.38 |
| 20/20 Biolabs Inc. (AIDX)vs › | $4.21M | 1.99 | 1.05 | 3.08 | 3.15 |
| Nexalin Technology, Inc. (NXL)vs › | $3.57M | 1.25 | 6.05 | 6.00 | 4.06 |
| PharmaCyte Biotech, Inc. (PMCB)vs › | $4.40M | 40.30 | 26.48 | 43.98 | 50.08 |
| Evogene Ltd. (EVGN)vs › | $3.55M | 3.57 | 2.84 | 4.34 | 5.17 |
| Mustang Bio, Inc. (MBIO)vs › | $3.49M | 1.97 | 1.45 | 2.21 | 4.94 |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.52M | 2.81 | 3.29 | 4.75 | 4.47 |
Current Ratio
2.08
Quick Ratio
2.08
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-06-30 | 2.08 |
| 2026-03-31 | 3.36 |
| 2025-12-31 | 3.82 |
| 2025-09-30 | 4.03 |
| 2025-06-30 | 2.27 |
| 2025-03-31 | 0.67 |
| 2024-12-31 | 1.72 |
| 2024-09-30 | 1.70 |
| 2024-06-30 | 1.77 |
| 2024-03-31 | 1.92 |
| 2023-12-31 | 2.64 |
| 2023-09-30 | 3.09 |
| 2023-06-30 | 3.28 |
| 2023-03-31 | 4.91 |
| 2022-12-31 | 3.15 |
| 2022-09-30 | 3.16 |
| 2022-06-30 | 4.48 |
| 2022-03-31 | 1.75 |
| 2021-12-31 | 1.51 |
| 2021-09-30 | 1.82 |
| 2021-06-30 | 2.13 |
| 2021-03-31 | 2.14 |
| 2020-12-31 | 3.25 |
| 2020-09-30 | 4.13 |
| 2020-06-30 | 1.50 |
| 2020-03-31 | 2.12 |
| 2019-12-31 | 0.78 |
| 2019-09-30 | 0.99 |
| 2019-06-30 | 2.63 |
| 2019-03-31 | 3.15 |
| 2018-12-31 | 2.76 |
| 2018-09-30 | 3.91 |
| 2018-06-30 | 3.66 |
| 2018-03-31 | 4.47 |
| 2017-12-31 | 5.14 |
| 2017-09-30 | 7.76 |
| 2017-06-30 | 5.65 |
| 2017-03-31 | 5.35 |
| 2016-12-31 | 3.65 |
| 2016-09-30 | 5.21 |
| 2016-06-30 | 2.34 |
| 2016-03-31 | 3.45 |
| 2015-12-31 | 1.76 |
| 2015-09-30 | 0.00 |
| 2015-06-30 | 0.00 |
| 2015-03-31 | 0.00 |
